Revolution Medicines Inc. soared the most in six years after its treatment for an aggressive form of pancreatic cancer boosted patients’ survival in a late-stage trial, marking a significant breakthrough in the especially deadly condition.
Patients with metastatic pancreatic cancer given Revolution’s daraxonrasib showed statistically significant improvements in a measure of tumor growth and overall survival compared to those given chemotherapy, the company said Monday. Median overall survival was 13.2 months on the experimental medicine compared to 6.7 months for chemotherapy, the current standard of care.
Revolution’s shares gained 37% when markets opened in New York on Monday, its biggest ...